Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07439653 · ClinicalTrials.gov registry record · Phase 1
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1 study, sponsored by TORL Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT07439653 is a Phase 1 study that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 155 participants.
The verdict
NCT07439653, a Phase 1 study, is actively recruiting participants, sponsored by TORL Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Interventions
- DRUG TORL-5-700
- DRUG TORL-5-700 at MTD/RP2D
- DRUG TORL-5-700 at MTD/RP2D in combination with another agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2029-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07439653
The ClinicalTrials.gov registry entry for NCT07439653 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TORL Biotherapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TORL-5-700 is the first listed.
NCT07439653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07439653 about?
NCT07439653 is a clinical study titled "A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma". A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
What is the current status of trial NCT07439653?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2026-03-31. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT07439653?
The interventions under investigation include: TORL-5-700 (DRUG), TORL-5-700 at MTD/RP2D (DRUG), TORL-5-700 at MTD/RP2D in combination with another agent (DRUG).
Who is sponsoring clinical trial NCT07439653?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.